GKOS 241018 110.00C (GKOS241018C110000) Stock Options, News & Quotes

US OptionsDetailed Quotes

GKOS241018C110000

Watchlist

18.56
+7.26+64.25%

15min DelayClose Sep 27 16:00 ET

18.58High18.55Low

Intraday

5D
Daily

News

Buy Rating on Glaukos: IDose's Market Potential and Strategic Advantages Outshine Ripple's RTC-620
TipRanksSep 23 05:55 ET · Ratings
Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement
GlobeNewswireSep 23 01:30 ET
Is There An Opportunity With Glaukos Corporation's (NYSE:GKOS) 50% Undervaluation?
Simply Wall StSep 18 11:05 ET
Daily short sale tracking: Intel's short volume increased by 10 million, with a short sale ratio of 13%
Moomoo NewsSep 18 09:00 ET
Glaukos Stocks Rides on Strong Product Demand Amid Competition
Zacks Sep 11 08:35 ET
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
Zacks Sep 9 14:00 ET

Comments

Moomoo AI

Jan 21 22:51

Glaukos' revenue growth is the market's focus due to its unprofitability. The 88% share price gain is solid, not standout. Market sentiment is lukewarm, hinting at potential stronger growth trends. Recent sentiment is positive due to strong share price momentum.

Investors Bid Glaukos (NYSE:GKOS) up US$137m Despite Increasing Losses YoY, Taking One-year Return to 88%

Meltyy

Dec 19, 2023 15:33

PDUFA Update…

Last week’s PDUFAs:
$Arcutis Biotherapeutics (ARQT.US)$ : Approved 12/15
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co (MRK.US)$ : Approved 12/15
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos (GKOS.US)$ : Approved 12/14
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co (MRK.US)$ : Approved ...

Meltyy

Dec 4, 2023 15:48

PDUFA Events for December 2023

The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics (CRSP.US)$ $Vertex Pharmaceuticals (VRTX.US)$ $OptiNose (OPTN.US)$ $Arcutis Biotherapeutics (ARQT.US)$ $Calliditas Therapeutics (CALT.US)$ $bluebird bio (BLUE.US)$ $Glaukos (GKOS.US)$ $Ionis Pharmaceuticals (IONS.US)$ $Amgen (AMGN.US)$ $Merck & Co (MRK.US)$

Moomoo AI

Nov 3, 2023 19:30

Glaukos' stock carries risk due to losses and high debt, despite cash reserves. The absence of EBIT level profits and free cash flow make sustainability questionable. Investors should proceed with caution.

Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Rockhoundj

Nov 5, 2022 15:23

Let’s see if this bounces

$Glaukos (GKOS.US)$
im seeing some decent chart upside here
thoughts?